Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma

BACKGROUND: Guidelines in 2013 and 2014 recommended Epidermal Growth Factor Receptor (EGFR) testing for metastatic lung adenocarcinoma patients as the efficacy of targeted therapies depends on the mutations. However, adherence to these guidelines and the corresponding costs have not been well-studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Chan, Holguin, Rolfy A. Perez, Schaefer, Eric, Zhou, Shouhao, Belani, Chandra P., Ma, Patrick C., Reed, Michael F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994894/
https://www.ncbi.nlm.nih.gov/pubmed/35397521
http://dx.doi.org/10.1186/s12913-022-07857-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994894/
https://www.ncbi.nlm.nih.gov/pubmed/35397521
http://dx.doi.org/10.1186/s12913-022-07857-y

Ejemplares similares